Liraglutide

Drug Profile

Liraglutide

Alternative Names: LATIN T1D; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Developer Cedars-Sinai Medical Center; Hvidovre Hospital; Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 05 Sep 2017 Novo Nordisk reaches a resolution with the US Federal government and the states about an investigation concerning sales and marketing practices for Victoza®
  • 28 Aug 2017 Post-hoc efficacy data from the phase IIIb LEADER trial in Type-2 diabetes mellitus released by Novo Nordisk
  • 25 Aug 2017 The US FDA approves liraglutide to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top